Literature DB >> 8202044

Langerhans cell histiocytosis and etoposide: risks vs. benefits.

G J D'Angio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8202044     DOI： 10.1002/mpo.2950230202

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN： 0098-1532


× No keyword cloud information.
  2 in total

1.  Risk of etoposide-related acute myeloid leukemia in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.

Authors:  Shinsaku Imashuku; Tomoko Teramura; Kikuko Kuriyama; Junichi Kitazawa; Etsuro Ito; Akira Morimoto; Shigeyoshi Hibi
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

2.  A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group.

Authors: 
Journal:  Arch Dis Child       Date:  1996-07       Impact factor: 3.791
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.